Amgen, Syapse enters precision medicine collaboration in Oncology
Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology.
New Delhi: American multinational biopharmaceutical firm Amgen and Syapse, a company powering precision medicine insights through its global provider network, recently announced a precision medicine collaboration in oncology.
Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology. This effort will identify existing patients within the Syapse Learning Health Network that could be eligible for Amgen-sponsored clinical trials and seek to bring these trials to community health system sites.
The companies will create opportunities for physicians and researchers within the Syapse Network to gain access to analytics, real-world evidence-based insights, and collaborative research opportunities. Amgen will have access to real-world evidence for potential use in regulatory filings in support of certain agreed upon development candidates in oncology. Amgen will also work with Syapse to develop real-world evidence standards to support the acceleration of therapies to market.
Commenting on the same, Mike Nohaile, senior vice president of Strategy, Commercialization and Innovation at Amgen said, “As cancer remains one of the leading causes of death around the world, emerging software and data analytic tools are creating exciting opportunities to more rapidly develop and deliver targeted treatment options to patients.”
“Our collaboration with Syapse supports this effort by leveraging real-world evidence to accelerate bringing new oncology treatments to market and empowers healthcare providers with more robust insights and decision-making tools to improve patient care, ” Mike added.
Expressing his opinion over the collaboration, Ken Tarkoff, chief executive officer at Syapse said, “Syapse and Amgen share a common vision of ensuring that all cancer patients, regardless of income or location, receive access to the best possible care.”
“Through this collaboration and the strategic relationships we’ve built with community health systems globally, we aim to develop evidence of clinical utility that can be used to bring molecularly targeted treatments to market more quickly and ensure more diverse groups of patients can access them, ” he added.